Mynewsdesk LinkedIn

The next generation biopharmaceuticals

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Affibodys latest Press releases

To the archive

2021-06-02

Notice to attend Annual General Meeting

The shareholders of Affibody Medical AB (publ), corporate identity number 556714-5601 (the “Company” or “Affibody”) are hereby given notice to the Annual General Meeting...[read more]

2021-05-14

Interim Report – January to March 2021...[read more]

2021-03-09

Affibody and Inmagene announce IND Clearance for izokibep (ABY-035) for the...[read more]

Affibody’s proprietary technology offers several key advantages over current targeted approaches

Research & Development

Multi-specific formats enabling bi-specific binding and extended half-life

Site-specifically modified drug conjugates with excellent tox profile and high tumor uptake

Biodistribution flexibility and good tissue penetration to reach targets that are difficult to reach for antibodies